Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
Reffelmann
Thorsten
T
The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA 90017-2395, USA.
Kloner
Robert A
RA
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003326:Coronary Circulation / Q000187:drug effects; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D009928:Organ Specificity; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011652:Pulmonary Circulation / Q000187:drug effects; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D020301:Vasospasm, Intracranial / Q000188:drug therapy
D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human